Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.72
Bid: 18.72
Ask: 18.98
Change: 0.04 (0.21%)
Spread: 0.26 (1.389%)
Open: 18.72
High: 18.72
Low: 18.72
Prev. Close: 18.85
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

28 Jul 2023 17:23

RNS Number : 6268H
Nanoco Group PLC
28 July 2023
 

28 July 2023

NANOCO GROUP PLC

("Nanoco", the "Group" or the "Company")

 

Exercise of Options and Issue of Shares to Employee Benefit Trust

 

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY

 

Nanoco announces that it has issued 1,985,206 new Ordinary Shares of 10 pence each in the Company ("Ordinary Shares"). All of the shares were issued at par value, pursuant to a subscription by the Company's Employee Benefit Trust ('EBT') to satisfy share awards granted to employees under the Company's shareholder approved Deferred Bonus Plan. The issue of new shares enables the company to provide the shares without any cash cost and minimal dilution to existing shareholders.

On 26 July 2023 Nanoco Group plc ("Nanoco") received notice that Brian Tenner, CEO, was exercising in full options granted to him in October and December 2019. Mr Tenner's entire bonus award for the financial year ending 31 July 2019 had been issued as deferred share options which were then subject to a two year holding period. The options vested in full in October and December 2021. Details of the exercise are shown in the table below.

On 26 July 2023 Nanoco received notice that Dr Nigel Pickett, CTO, was exercising in full options granted to him in October and December 2019. Dr Pickett's entire bonus award for the financial year ending 31 July 2019 had been issued as deferred share options which were then subject to a two year holding period. Dr Pickett has also exercised options granted to him in November 2016 in respect of the deferred bonus award for the financial year ending 31 July 2016 and which were also then subject to a two year holding period. The options vested in full in November 2018. Details of the exercises are shown in the table below.

Brian Tenner, CEO, and Nigel Pickett, CTO, have both exercised their respective awards and utilised the cash proceeds of selling a proportion of shares to fund their personal tax obligations and dealing fees, while retaining the balance in full thereby increasing their shareholdings by 551,946 shares and 498,336 shares respectively.

Application was made to the FCA for the 1,985,206 new Ordinary Shares to be admitted to the premium segment of the Official List and to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on its main market for listed securities. Admission became effective on 27 July 2023, and dealings in the new Ordinary Shares have now commenced. The new Ordinary Shares rank pari passu in all respects with the existing Ordinary Shares.

Following Admission, the Company's issued share capital comprised 324,430,950 Ordinary Shares, of which 12,222 were previously held in treasury and remain so. Each Ordinary Share carries the right to one vote and, therefore, the total number of voting rights in the Company on Admission will be 324,418,728. This figure may be used by Shareholders and other investors as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The details of the awards and subsequent exercise and retention of shares are as follows:

Name of Director / PDMR

Number of options exercised

Number of shares sold to meet tax and fee obligations

Shares retained following exercise

Total shareholding

Brian Tenner (CEO - Director) - 2019 award

1,043,268

(491,322)

551,946

1,157,834

Dr Nigel Pickett (CTO - Director) 2019 award

875,362

(412,248)

463,114

11,770,911

Dr Nigel Pickett (CTO - Director) 2016 award

66,576

(31,354)

35,222

(inc above)

 

This notification is made pursuant to the Disclosure and Transparency Rules.

For further information please contact:

Liam Gray

Chief Financial Officer and Company Secretary

Telephone : +44 (0) 1928 761422

 

Notes for editors:

About Nanoco Group plc

Nanoco (LSE: NANO) harnesses the power of nano-materials. Nano-materials are materials with dimensions typically in the range 1 - 100 nm. Nano-materials have a range of useful properties, including optical and electronic. Quantum dots are a subclass of nano-material that have size-dependent optical and electronic properties. The Group produces quantum dots and other nano-materials. Within the sphere of quantum dots, the Group exploits different characteristics of the quantum dots to target different performance criteria that are attractive to specific markets or end-user applications such as the Display, Sensor and Electronics markets. An interesting property of quantum dots is their absorption spectrum. Nanoco's HEATWAVE™ quantum dots can be tuned to absorb light at different wavelengths across the near-infrared spectrum, rendering them useful for applications including image sensors. Another interesting property of quantum dots is photoluminescence: the emission of longer wavelength light upon excitation by light of a shorter wavelength. The colour of light emitted depends on the particle size. Nanoco's CFQD® quantum dots are free of cadmium and other toxic heavy metals, and can be tuned to emit light at different wavelengths across the visible and infrared spectrum, rendering them useful for a wide range of applications including displays, lighting and biological imaging.

Nanoco was founded in 2001 and is headquartered in Runcorn, UK, with a US subsidiary, Nanoco Inc., in Concord, MA. Nanoco continues to build out a world-class, patent-protected IP portfolio generated both by its own innovation engine, as well as through acquisition.

Nanoco is listed on the Main Market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocotechnologies.com.

Notification of Dealing Form

1.

Details of the Person Discharging Managerial Responsibilities ("PDMR") / person closely associated with them ("PCA")

a)

Name

BRIAN TENNER

2.

Reason for the notification

a)

Position /status

CHIEF EXECUTIVE OFFICER

b)

Initial notification / amendment

INITIAL NOTIFICATION

3.

Details of the Issuer

a)

Name

NANOCO GROUP PLC

b)

LEI code

213800HOSJEZO1KOCV33

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Type of instrumentIdentification code

ORDINARY SHARES OF 1O PENCE EACH

ISIN: GB00B01JLR99

b)

Nature of the transaction

EXERCISE OF AN OPTION OVER ORDINARY SHARES UNDER THE NANOCO 2015 DEFERRED BONUS PLAN AND SALE OF SUFFICIENT SHARES TO FUND INCOME TAX AND NATIONAL INSURANCE CHARGES. BALANCE RETAINED.

c)

Price(s) and volume(s)

Acquisition of shares on exercise of option

 Sale of shares to pay tax and costs

Price(s)

 

Volume(s)

Nil cost

18p

1,043,268

491,322

d)

Aggregated information:- Aggregated volume- Price

N/A

e)

Date of the transaction

28 JULY 2023

f)

Place of the transaction

LONDON STOCK EXCHANGE, MAIN MARKET

Notification of Dealing Form

1.

Details of the Person Discharging Managerial Responsibilities ("PDMR") / person closely associated with them ("PCA")

a)

Name

DR NIGEL PICKETT

2.

Reason for the notification

a)

Position /status

CHIEF TECHNICAL OFFICER

b)

Initial notification / amendment

INITIAL NOTIFICATION

3.

Details of the Issuer

a)

Name

NANOCO GROUP PLC

b)

LEI code

213800HOSJEZO1KOCV33

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Type of instrumentIdentification code

ORDINARY SHARES OF 1O PENCE EACH

ISIN: GB00B01JLR99

b)

Nature of the transaction

EXERCISE OF AN OPTION OVER ORDINARY SHARES UNDER THE NANOCO 2015 DEFERRED BONUS PLAN AND SALE OF SUFFICIENT SHARES TO FUND INCOME TAX AND NATIONAL INSURANCE CHARGES. BALANCE RETAINED.

c)

Price(s) and volume(s)

Acquisition of shares on exercise of option

Acquisition of shares on exercise of option

 Sale of shares to pay tax and costs

Price Volume

Nil cost 875,362

 

Nil cost 66,576

18p 443,602

d)

Aggregated information:- Aggregated volume- Price

N/A

e)

Date of the transaction

28 JULY 2023

f)

Place of the transaction

LONDON STOCK EXCHANGE, MAIN MARKET

= END =

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHNKFBBABKDBOB
Date   Source Headline
19th Aug 20228:21 amRNSLitigation Update – Pre-Trial Conference
18th Aug 20224:10 pmRNSDirector/PDMR Shareholding
16th Aug 20227:00 amRNSTrading Update
28th Jul 202210:42 amRNSHolding(s) in Company
13th Jul 20222:03 pmRNSReplacement - Director/PDMR Shareholding
13th Jul 202212:00 pmRNSHolding(s) in Company
13th Jul 202212:00 pmRNSDirector/PDMR Shareholding
13th Jul 202212:00 pmRNSHolding(s) in Company
30th Jun 20227:00 amRNSTotal Voting Rights
29th Jun 20227:00 amRNSChange of Auditor
23rd Jun 20223:48 pmRNSDirector/PDMR Shareholding
22nd Jun 20222:25 pmRNSHolding(s) in Company
21st Jun 20223:36 pmRNSDirector/PDMR Shareholding
21st Jun 20229:06 amRNSReplacement: Director/PDMR Shareholding
21st Jun 20227:00 amRNSDirector/PDMR Shareholding
17th Jun 20224:36 pmRNSPrice Monitoring Extension
17th Jun 202210:45 amRNSHolding(s) in Company
14th Jun 20229:42 amRNSHolding(s) in Company
9th Jun 20227:00 amRNSBlock listing Six-monthly Return
8th Jun 202212:00 pmRNSResults of Fundraise
8th Jun 20227:00 amRNSFundraise significantly over-subscribed
7th Jun 20225:16 pmRNSReplacement: Litigation Update
7th Jun 20224:55 pmRNSLitigation Update
6th Jun 20227:02 amRNSTrading Update & Proposed Fundraise
6th Jun 20227:00 amRNSMajor Work Package for European Customer
23rd May 20225:00 pmRNSHolding(s) in Company
17th May 20227:02 amRNSLitigation Update
13th May 202212:15 pmRNSHolding(s) in Company
13th Apr 20222:49 pmRNSHolding(s) in Company
12th Apr 20227:00 amRNSInterim Results
17th Mar 20227:00 amRNSAdditional Work Package for European Customer
15th Mar 20227:00 amRNSNotice of Interim Results
4th Feb 20223:14 pmRNSHolding(s) in Company
31st Jan 20227:00 amRNSTotal Voting Rights
9th Dec 20217:00 amRNSBlock listing Six-Monthly Return
2nd Dec 20217:18 amRNSBlock Listing Application
1st Dec 202112:30 pmRNSDirector/PDMR Shareholding
1st Dec 202112:28 pmRNSAnnual General Meeting – Voting Results
30th Nov 20217:00 amRNSAGM Statement
18th Nov 20211:13 pmRNSDirector/PDMR Shareholding
9th Nov 20217:11 amRNSDirector/PDMR Shareholding
8th Nov 20217:00 amRNSDirector Appointment
5th Nov 202111:25 amRNSAdditional Work Package for European Customer
4th Nov 20216:20 pmRNSNotice of AGM
3rd Nov 20217:00 amRNSPreliminary Results
18th Oct 20216:10 pmRNSChange to final results announcement date
13th Oct 20219:30 amRNSPresentation via Investor Meet Company
8th Oct 20211:48 pmRNSNotice of Results
19th Aug 20217:00 amRNSNon-Executive Director Appointment
16th Jul 20214:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.